Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1500 participants
OBSERVATIONAL
2018-06-25
2028-06-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Modified Baveno Classification of Obstructive Sleep Apnoea Based on Sleepiness and Cardiovascular Scores
NCT06861686
Comparison of Automatic CPAP to Fixed CPAP for OSAS Following a Prediction Formula
NCT00262366
Trial of Auto Continuous Positive Airway Pressure (CPAP)
NCT01064258
Sleep Schedules Modifications in Sleep Apnea Patients Treated by nCPAP
NCT01355419
Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment
NCT02583906
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
CSA is defined as: (1) an apnea/hypopnea index ≥ 15 per hour of sleep and (2) the number of central apneas and/or hypopneas is \> 50% of the total number of apneas and hypopneas.
Presence of CSA is associated with excessive daytime sleepiness and poor sleep quality. Furthermore, in patients with heart failure, presence of CSA was found to be related to mortality. As yet, however, there is insufficient knowledge on the clinical features, pathophysiological background and consecutive algorithms for treatment. Currently, it is not fully clear whether CSA or the treatment of CSA is related to disease progress.
The aim of this trial is to evaluate the current treatment choices for CSA in Belgium and compliance with and effects of these treatments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Central Sleep Apnea
Subjects with an apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events \> 50%, derived from polysomnography (diagnostic or during positive airway pressure treatment)
No intervention
Routine care (registry)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
Routine care (registry)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* An apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events \> 50%, derived from polysomnography (diagnostic or during (PAP) treatment)
* Written informed consent provided
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philips Respironics
INDUSTRY
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dries Testelmans, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
UZ Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
OLV Ziekenhuis
Aalst, , Belgium
ZNA Middelheim
Antwerp, , Belgium
UZA
Antwerp, , Belgium
AZ Sint-Jan
Bruges, , Belgium
CHU Saint-Pierre
Brussels, , Belgium
Ghent University Hospital
Ghent, , Belgium
Jessa Ziekenhuis
Hasselt, , Belgium
AZ Groeninge
Kortrijk, , Belgium
CH Jolimont
La Louvière, , Belgium
UZ Leuven
Leuven, , Belgium
CHR de la Citadelle
Liège, , Belgium
CHU UCL Namur
Namur, , Belgium
AZ Glorieux
Ronse, , Belgium
AZ Turnhout
Turnhout, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Berend-Jan Berendes, MD
Role: primary
Lieven Bedert, MD
Role: primary
Johan Verbraecken, MD, PhD
Role: primary
Veerle Ringoet, MD
Role: primary
Marie Bruyneel, MD, PhD
Role: primary
Katrien Hertegonne, MD, PhD
Role: primary
Karolien Weytjens, MD
Role: primary
Sofie Maddens, MD
Role: primary
Alain Volckaert, MD
Role: primary
Dries Testelmans, MD, PhD
Role: primary
Farhad Baharloo, MD
Role: primary
Thibaut Vandenhove, MD
Role: primary
Edwin Hill, MD
Role: primary
Maryse Van den Heuvel, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B322201835950
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.